预防性脑照射的临床共识与进展

摘要/Abstract

摘要：预防性脑照射是临床上处理肿瘤脑转移的有效手段，该手段对于微小病灶的杀灭能够有效降低脑转移的发生率，改善患者预后。其有效性在小细胞肺癌中得到了验证，而在非小细胞肺癌（NSCLC）以及乳腺癌中的应用仍然处于探索阶段，对于手术及辅助化疗后ⅢAN2期NSCLC患者以及曲妥珠单抗治疗的人表皮生长因子受体2阳性的乳腺癌患者，预防性脑照射有望成为这两类患者的常规治疗手段。

关键词:颅脑照射,肺肿瘤,,乳腺肿瘤

Abstract:Prophylactic cranial irradiation is an effective means of dealing with brain metastasis of cancer, which can reduce the incidence of brain metastasis by killing the micrometastasis and then improve the prognosis. The effectiveness has been verified in small cell lung cancer, but the application is still in the exploration in nonsmall cell lung cancer （NSCLC） and breast cancer. Prophylactic cranial irradiation is expected to become the conventional treatment for patients with NSCLC of ⅢAN2 stage after operation and adjuvant chemotherapy or breast cancer of epithelial growth factor receptorpositive after receiving trastuzumab.

Key words:Cranial irradiation,Lung neoplasms,Breast neoplasms

柳燕冬,周菊英. 预防性脑照射的临床共识与进展[J]. 国际肿瘤学杂志, 2017, 44(3): 217-220.

Liu Yandong, Zhou Juying. Clinical consensus and progress of prophylactic cranial irradiation[J]. Journal of International Oncology, 2017, 44(3): 217-220.

参考文献

［1］ Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with smallcell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group［J ］. N Engl J Med, 1999, 341(7): 476-484. DOI: 10.1056/NEJM199908123410703. ［2］ Schild SE, Foster NR, Meyers JP, et al. Prophylactic cranial irradiation in smallcell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis［J］. Ann Oncol, 2012, 23(11): 2919 -2924. DOI:10.1093/annonc/mds123. ［3］ Zhang W, Jiang W, Luan L, et al. Prophylactic cranial irradiation for patients with smallcell lung cancer: a systematic review of the literature with metaanalysis［J］. BMC Cancer, 2014, 14: 793. DOI: 10.1186/1471240714793. ［4］ Rule WG, Foster NR, Meyers JP, et al. Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis［J］. J Geriatr Oncol, 2015, 6(2): 119-126. DOI:10.1016/j.jgo.2014.11.002. ［5］ Le Péchoux C, Dunant A, Senan S, et al. Standarddose versus higher dose prophylactic cranial irradiation (PCI) in patients with limitedstage smallcell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 9901, EORTC 2200308004, RTOG 0212, and IFCT 9901): a randomised clinical trial［J］. Lancet Oncol, 2009, 10(5): 467-474. DOI: 10.1016/S14702045(09)701019. ［6］ Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase Ⅱrandomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limiteddisease smallcell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(1): 7784. DOI: 10.1016/j.ijrobp.2010.05.013. ［7］ Sun A, Bae K, Gore EM, et al. Phase Ⅲ trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non smallcell lung cancer: neurocognitive and qualityoflife analysis［J ］. J Clin Oncol, 2011, 29(3): 279-286. DOI: 10.1200/JCO.2010.29.6053. ［8］ Won YW, Joo J, Yun T, et al. A nomogram to predict brain metastasis as the first relapse in curatively resected nonsmall cell lung cancer patients［J］. Lung Cancer, 2015, 88(2): 201-207. DOI: 10.1016/j.lungcan.2015.02.006. ［9］ Zhang F, Zheng W, Ying L, et al. A nomogram to predict brain metastases of resected nonsmall cell lung cancer patients［J］. Ann Surg Oncol, 2016, 23(9): 30333039. DOI: 10.1245/s1043401652063. ［10］ Lee DS, Kim SJ, Kang JH, et al. Serum carcinoembryonic antigen levels and the risk of wholebody metastatic potential in advanced nonsmall cell lung cancer［J］. J Cancer, 2014, 5(8): 663-669. DOI: 10.7150/jca.9871. ［11］ Horinouchi H, Sekine I, Sumi M, et al. Brain metastases after definitive concurrent chemoradiotherapy in patients with stage Ⅲ lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor［ J］. Cancer Sci, 2012, 103(4): 756-759. DOI: 10.1111/j.13497006201202217.x. ［12］ Hubbs JL, Boyd JA, Hollis D, et al. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer［J］. Cancer, 2010, 116(21): 5038-5046. DOI: 10.1002/cncr.25254. ［13］ Gore EM, Bae K, Wong SJ, et al. Phase Ⅲ comparison of prophylactic cranial irradiation versus observation in patients with locally advanced nonsmallcell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214［J］. J Clin Oncol, 2011, 29(3): 272-278. DOI: 10.1200/JCO.2010.29.1609. ［14］ Xie SS, Li M, Zhou CC, et al. Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with nonsmall cell lung cancer: a systematic review and metaanalysis［J］. PLoS One, 2014, 9(7): e103431. DOI: 10.1371/journal.pone.0103431. ［15］ Li N, Zeng ZF, Wang SY, et al. Randomized phase Ⅲ trial of prophylactic cranial irradiation versus observation in patients with fully resected stage ⅢAN2 nonsmallcell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy［J］. Ann Oncol, 2015, 26(3): 504-509. DOI: 10.1093/annonc/mdu567. ［16］ Niwińska A. Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment［J］. Clin Exp Metastasis, 2016, 33(7): 677-685. DOI: 10.1007/s1058501698021. ［17］ Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases［J］. Cancer, 2006, 107(4): 696-704. DOI: 10.1002/cncr.22041. ［18］ Graesslin O, Abdulkarim BS, Coutant C, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer［J］. J Clin Oncol, 2010, 28(12): 2032-2037. DOI: 10.1200/JCO.2009.24.6314. ［19］ HedayatizadenOmran A, Rafiei A, AlizadenNavaei R, et al. Role of HER2 in brain metastasis of breast cancer: a systematic review and metaanalysis［J］. Asian Pac J Cancer Prev, 2015, 16(4): 1431-1434. ［20］ Canney P, Murray E, DixonHughes J, et al. A prospective randomised phase Ⅲ clinical trial testing the role of prophylactic cranial radiotherapy in patients treated with trastuzumab for metastatic breast canceranglo celtic Ⅶ［J］. Clin Oncol (R Coll Radiol), 2015, 27 (8): 460-464. DOI: 10.1016/j.clon.2015.04.033.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[5]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[6]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[7]	贺嘉慧, 胡钦勇.基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[8]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[9]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[10]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[11]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰.miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[12]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[13]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[15]	周婷, 徐少华, 梅林.贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.